TABLE 1.
HBcAg-specific CD4+ Th1 T cells inhibit in vivo production of HBcAg-specific human IgG in hu-PBL-NOD/SCID mice
| Exptl groupa | Mouse | HBcAg-specific human IgG produced with PBL from CHB donorb
|
|||
|---|---|---|---|---|---|
| HLA-DR13 positive
|
HLA-DR13 negative
|
||||
| Wk 1 | Wk 2 | Wk 1 | Wk 2 | ||
| Group 1 | NOD1 | <1/50 | 1/200 | 1/3,200 | 1/12,800 |
| NOD2 | <1/50 | 1/1,600 | 1/3,200 | 1/12,800 | |
| NOD3 | <1/50 | 1/100 | 1/1,600 | 1/6,400 | |
| Group 2 | NOD1 | 1/400 | 1/3,200 | 1/3,200 | 1/12,800 |
| NOD2 | 1/1,600 | 1/3,200 | 1/3,200 | NA | |
| NOD3 | 1/200 | 1/800 | |||
| Group 3 | NOD1 | 1/1,600 | 1/12,800 | 1/3,200 | 1/25,600 |
| NOD2 | 1/1,600 | 1/12,800 | 1/3,200 | 1/25,600 | |
| NOD3 | 1/800 | 1/12,800 | 1/6,400 | 1/25,600 | |
| Group 4 | NOD1 | <1/50 | 1/100 | 1/3,200 | NA |
| NOD2 | 1/800 | 1/6,400 | 1/3,200 | NA | |
| NOD3 | 1/800 | ||||
a
Group 1, T cells plus PBL plus HBcAg; group 2, T cells plus PBL plus no antigen; group 3, PBL plus HBcAg; group 4, PBL plus no antigen.
b
Results are end-point dilution titers. NA, not available.